A Food and Drug Administration advisory committee voted against approval for EDAP TMS's (Nasdaq: EDAP) prostate cancer treatment Ablatherm-HIFU device sending the stock price plummeting $1.49 to $1.93.
FDA panel rejects EDAP's cancer treatment
July 31, 2014 at 13:02 PM EDT